• Title/Summary/Keyword: H1N1 Subtype

검색결과 75건 처리시간 0.022초

2003-2004 절기 서울지역의 인플루엔자 바이러스 분리 및 아형 분석 (Analysis of Influenza Virus Isolates in Seoul during 2003-2004 Season)

  • 황영옥;이재인;서병태
    • 미생물학회지
    • /
    • 제41권1호
    • /
    • pp.53-59
    • /
    • 2005
  • 인플루엔자바이러스는 거의 매년 겨울철에 유행을 일으키는 급성 호흡기 질환의 주요한 원인 바이러스중의 하나로 막대한 사회 경제적 손실을 가져온다. 본 실험은 2003-2004절기 동안 $38^{\circ}C$이상의 갑작스러운 발열과 더불어 기침 또는 인후통을 보이는 401명의 인플루엔자의사환자(ILI : Influenza-like illness) 검체로부터 124주의 인플루엔자바이러스를 분리하여 형 및 아형 분석과 그에 따른 유행양상을 분석하였다. 인플루엔자 의사환자 연령별 분포를 살펴보면 20-49세의 성인층의 환자수가 $23\%$로 가장 많았으며, 바이러스 분리율은 7-19세의 학령기에서 $50\%$로 가장 높았다. 분리된 인플루엔자바이러스 124주 중 A/H3N2 type는 83주, Type B는 41주였다. 지역별 인플루엔자 의사환자 발생율은 노원구, 서초구, 강남구의 발생율이 타 지역에 비해 비교적 높았으며 바이러스 분리율은 용산구 $66.7\%$, 강남구 $50.0\%$, 노원구 $39.9\%$, 강북구 $36.8\%$ 서초구 $27.8\%$, 동작구 $21.2\%$ 순이었다. 인플루엔자 의사환자의 예방접종현황조사결과 접종을 받았음에도 불구하고 인플루엔자 의사환자로 보고된 경우가 $40\%$였으며, 접종율은 20-49세 성인층이 가장 높았다. 이와 같은 인플루엔자 실험실 표본감시체계 결과의 분석을 통하여 새로운바이러스형 출현을 감시하며, 현행 예방백신의 효과 및 유행양상을 예측하여 국가 인플루엔자 관리대책을 수립하는데 활용하고자 한다.

영지버섯추출물 및 에르고스테롤의 냉감 수용체 TRPM8 (Transient Receptor Potential Cation Channel Melastatin Subtype 8) 발현 유도 효과 (Inductive Effects of the Cold Receptor TRPM8 Expression in Ganoderma lucidum Extracts and Ergosterol)

  • 유화선;정지연;전원옥;이춘몽;이정노;박성민
    • 대한화장품학회지
    • /
    • 제44권1호
    • /
    • pp.15-21
    • /
    • 2018
  • UV 뿐 아니라 가시광선, 적외선에 의해 발생된 열로 인해 피부 온도 상승, MMP-1의 증가에 따른 피부 노화가 진행된다. 따라서 열에 의한 노화에서 피부 온도 조절은 노화 억제에 중요한 핵심 요소이다. 일시적인 수용체 전위 통로인 TRPM8은 멘솔 수용체(CMR1)로써 $25^{\circ}C$ 이하의 온도에서 활성화되고 시원한 감각을 발생시키는 냉 수용체로 보고되어 있다. TRPM8 조절을 통해 시원한 감각과 피부 온도를 조절하는 연구가 활발히 진행되고 있다. 본 연구에서는 천연물인 영지버섯을 이용하여 냉 수용체인 TRPM8 발현에 어떠한 영향을 주는지 확인하였다. 영지버섯추출물 및 용매 분획물의 TRPM8 발현에 대한 영향을 측정한 결과, 영지버섯추출물, n-hexane 분획물 및 water 분획물에서 농도의존적으로 TRPM8 발현이 증가함을 확인하였다. Hex 분획물에서 유효성분을 찾고자 크로마토그래피를 실시하여 1개의 화합물을 분리하였으며 $^1H$$^{13}C$ NMR spectrum 분석을 통하여 화학구조를 동정하였다. 분리된 화합물은 에르고스테롤로 TRPM8 발현 증가에 효과가 있음을 확인하였다. 결과를 토대로, 영지버섯추출물 및 에르고스테롤은 화장품 분야에서 새로운 쿨링 소재로서 개발가능성이 있다고 사료된다.

마우스 동계골수이식 후 면역체계의 재생: II. B림프구의 재생 및 항체산생 (Regeneration of Immune System after Syngeneic Bone Marrow Transplantation in Irradiated Mice: II. B Lymphocyte Regeneration and Antibody Production)

  • 김성호;오헌;이송은;김순태;조성기;현병화;류시윤
    • 한국수의병리학회지
    • /
    • 제1권1호
    • /
    • pp.7-12
    • /
    • 1997
  • Lethally irradited C3H/HeN mice were transplanted with syngeneic bone marrow. The B cell regeneration levels of spontaneous serum Ig, fecal igA and specific ig to diphtheria toxoid were determined at various time points. The number of B220+ cells reached normal range at 4 weeks after bone marrow transplantation(BMT) in spleen and lymph node. The B cell number of spleen returned to normal relatively soon than in the lymph node. Within 5 to 7 weeks after BMT, the transplanted mice contained nearly normal levels of spontaneous serum IgA, IgG2b and fecal IgA, but 2 fold lower levels of serum IgG2a, IgM and IgG3. Especially IgG3 levels were within low-normal range throughout the study. One to two weeks after immunization the predominant anti-diphtheria toxoid subtype was IgM. The levels of specific serum Ig were very low and after booster immunization at week 6, the short-lasting increase of Ig production was notd.

  • PDF

Modulation of Pituitary Somatostatin Receptor Subtype (sst1-5) mRNA Levels by Growth Hormone (GH)-Releasing Hormone in Purified Somatotropes

  • Park, Seung-Joon;Park, Hee-Soon;Lee, Mi-Na;Sohn, Sook-Jin;Kim, Eun-Hee;Jung, Jee-Chang;Frohman, Lawrence A.;Kineman, Rhonda D.
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제7권2호
    • /
    • pp.79-84
    • /
    • 2003
  • We have previously reported that expression of the somatostatin receptor subtypes, sst1-5, is differentially regulated by growth hormone (GH)-releasing hormone (GHRH) and forskolin (FSK), in vitro. GHRH binds to membrane receptors selectively located on pituitary somatotropes, activates adenylyl cyclase (AC) and increases sst1 and sst2 and decreases sst5 mRNA levels, without significantly altering the expression of sst3 and sst4. In contrast FSK directly activates AC in all pituitary cell types and increases sst1 and sst2 mRNA levels and decreases sst3, sst4 and sst5 expression. Two explanations could account for these differential effects: 1) GHRH inhibits sst3 and sst4 expression in somatotropes, but this inhibitory effect is masked by expression of these receptors in unresponsive pituitary cell types, and 2) FSK inhibits sst3 and sst4 expression levels in pituitary cell types other than somatotropes. To differentiate between these two possibilities, somatotropes were sequentially labeled with monkey anti-rat GH antiserum, biotinylated goat anti-human IgG, and streptavidin-PE and subsequently purified by fluorescent-activated cell sorting (FACS). The resultant cell population consisted of 95% somatotropes, as determined by GH immunohistochemistry using a primary GH antiserum different from that used for FACS sorting. Purified somatotropes were cultured for 3 days and treated for 4 h with vehicle, GHRH (10 nM) or FSK ($10{\mu}M$). Total RNA was isolated by column extraction and specific receptor mRNA levels were determined by semi-quantitative multiplex RT-PCR. Under basal conditions, the relative expression levels of the various somatostatin receptor subtypes were sst2>sst5>sst3=sst1> sst4. GHRH treatment increased sst1 and sst2 mRNA levels and decreased sst3, sst4 and sst5 mRNA levels in purified somatotropes, comparable to the effects of FSK on purified somatotropes and mixed pituitary cell cultures. Taken together, these results demonstrate that GHRH acutely modulates the expression of all somatostatin receptor subtypes within GH-producing cells and its actions are likely mediated by activation of AC.

Regulation of Prolactin Secretion: Dopamine is the Prolactin-release Inhibiting Factor (PIF), but also Plays a Role as a Releasing Factor (PRF)

  • Shin, Seon H.;Song, Jin-Hyang;Ross, Gregory M.
    • Animal cells and systems
    • /
    • 제3권2호
    • /
    • pp.103-113
    • /
    • 1999
  • Many in-depth reviews related to regulations of prolactin secretion are available. We will, therefore, focus on controversial aspects using personal opinion in this review. The neuroendocrine control of prolactin secretion from the anterior pituitary gland involves multiple factors including prolactin-release inhibiting factor (PIF) and prolactin releasing factor (PRF). The PIF exerts a tonic inhibitory control in the physiological conditions. The PIF should be able to effectively inhibit prolactin release or a lifetime, but the inhibitory action of dopamine cannot be sustained for a long period of time. Perifusion of a high concentration of dopamine (l ,000 nM) could not sustain inhibitory action on prolactin release but when a small amount of ascorbic acid (0.1 mM) is added in a low concentration of dopamine (3 nM) solution, prolactin release was inhibited for a long period. Ascorbate is essential for dopamine action to inhibit prolactin release. We have, therefore, concluded that the PIF is dopamine plus ascorbate. The major transduction system for dopamine to inhibit prolactin release is the adenylyl cyclase system. Dopamine decreases cyclic AMP concentration by inhibiting adenylyl cyclase, and cyclic AMP stimulates prolactin release. However, the inhibitory mechanism of dopamine on prolactin release is much more complex than simple inhibition of CAMP production. The dopamine not only inhibits cyclic AMP synthesis but also inhibits prolactin release by acting on a link(s) after the CAMP event in a chain reaction for inhibiting prolactin release. Low concentrations of dopamine stimulate prolactin release. Lactotropes are made of several different subtypes of cells and several different dopamine receptors are found in pituitary. The inhibitory and stimulatory actions induced by dopamine can be generated by different subtype of receptors. The GH$_4$ZR$_7$ cells express only the short isoform (D$_{2s}$) of the dopamine receptor, as a result of transfecting the D$_{2s}$ receptors into GH$_4$C$_1$ cells which do not express any dopamine receptors. When dopamine stimulates or inhibits prolactin release in GH$_4$ZR$_7$ cells, it is clear that the dopamine should act on dopamine D$_{2s}$ receptors since there is no other dopamine receptor in the GH$_4$ZR$_7$. Dopamine is able to stimulate prolactin release in a relatively low concentration while it inhibits in a high concentration in GH$_4$ZR$_7$. These observations indicate that the dopamine D$_2$ receptor can activate stimulatory and/or inhibitory transduction system depending upon dopamine concentrations.

  • PDF